Compare Episurf Medical AB with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
SEK 126 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.09
-122.53%
2.66
Revenue and Profits:
Net Sales:
4 Million
(Quarterly Results - Dec 2025)
Net Profit:
-14 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
118.31%
0%
118.31%
6 Months
93.75%
0%
93.75%
1 Year
-29.3%
0%
-29.3%
2 Years
-84.04%
0%
-84.04%
3 Years
-97.02%
0%
-97.02%
4 Years
-95.92%
0%
-95.92%
5 Years
-96.79%
0%
-96.79%
Episurf Medical AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
21.67%
EBIT Growth (5y)
2.07%
EBIT to Interest (avg)
-78.56
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.44
Sales to Capital Employed (avg)
0.17
Tax Ratio
0.56%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.11
EV to EBIT
-0.60
EV to EBITDA
-0.69
EV to Capital Employed
1.15
EV to Sales
3.06
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-190.98%
ROE (Latest)
-138.26%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
Bullish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
3.50
3.20
9.37%
Operating Profit (PBDIT) excl Other Income
-12.40
-9.40
-31.91%
Interest
0.10
0.20
-50.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-13.50
-10.40
-29.81%
Operating Profit Margin (Excl OI)
-4,114.30%
-3,500.00%
-61.43%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 9.37% vs 10.34% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is -29.81% vs 41.24% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
13.50
13.00
3.85%
Operating Profit (PBDIT) excl Other Income
-54.90
-71.30
23.00%
Interest
0.60
1.00
-40.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-58.20
-76.00
23.42%
Operating Profit Margin (Excl OI)
-4,481.50%
-5,946.20%
146.47%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 3.85% vs 26.21% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 23.42% vs 19.83% in Dec 2024
About Episurf Medical AB 
Episurf Medical AB
Pharmaceuticals & Biotechnology
Episurf Medical AB is a Sweden-based medical technology company. It is engaged in the development, manufacture and marketing of implants and surgical drilling templates used in the treatment of local cartilage damage in knee joints. The Company’s product portfolio includes the Episealer, and individually customized implant used as a cartilage replacement for early-stage patients; and Epiguide, a drill guide designed to attach to the knee’s surface, as well as related surgical tools. The personalization of implants and instruments is based on magnetic resonance imaging (MRI) and enables less invasive treatment. The process of ordering and creation of patient-specific implants and surgical instruments is covered by software suite, microiFidelity, comprising microiClinic, microiDesign and microiManufacture. The main shareholder of the Company is Serendipity Ixora Fund AB.
Company Coordinates 
Company Details
Karlavagen 60 , STOCKHOLM None : 114 49
Registrar Details






